The US Food and Drug Administration (FDA) has announced a recall of Mylanta and AlternaGel liquid antacids, making it the latest in a long line of Johnson & Johnson affiliated products to face a recall this year.
The products, which are manufactured by Johnson & Johnson-Merck Consumer Pharmaceuticals, Co. (JJMCP), are being recalled due to a labeling issue. Each of the 12 varieties of Mylanta and the one version of AlternaGel affected by the notice contain a trace amount of alcohol that was not revealed on the product labels, the company said in a statement.
“It is unlikely that use of these products will cause either alcohol absorption or alcohol sensitivity related adverse events,” J&J’s recall notice reports. “This is a wholesale and retail level recall and is not being undertaken on the basis of adverse events. No action is required by consumers or healthcare providers and consumers can continue to use the product.”
The specific varieties of each antacid being recalled are Mylanta Regular Strength Original, 12 ounce size; Mylanta Original, 5 ounce size; Mylanta Regular Strength Mint, 12 ounce size; Mylanta Maximum Strength Cherry, 12 ounce size; Mylanta Maximum Strength Mint, 12 ounce size; Mylanta Maximum Strength Original, 12 and 24 ounce sizes; Mylanta Ultimate Strength Mint, 12 ounce size; Mylanta Ultimate Strength Cherry, 12 ounce size; Mylanta Supreme Tasting with Calcium Cherry, 12 and 24 ounce sizes; and AlternaGel, 12 ounce size. Product codes are available on the FDA’s website.
Previously, on November 24, the company announced a recall of 9.3 million bottles of Tylenol-brand cold treatment, also for labels that failed to disclose the medicine’s alcohol content. Also last month, J&J pulled 4 million packages of Children’s Benadryl allergy tablets and 800,000 bottles of Junior Strength Motrin pain reliever/fever reducer caplets due to “insufficiencies in the development of the manufacturing process.”
According to Ransdell Pierson of Reuters, “All told, more than 200 million bottles of J&J products have been recalled in the past year”¦ The crisis has harmed J&J’s once-pristine image and is beginning to take a significant toll on its financial results. U.S. sales”¦ plunged 25 percent in the third quarter as scores of formulations became unavailable and customers opted instead for generic store brands.”
—
On the Net:
Comments